Prion disease-specific epitopes and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9809620-B2
Application number	US-201414265136-A
Country	US
Kind code	B2
Filing date	Apr 29, 2014
Priority date	Apr 30, 2013
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.

First claim

The invention claimed is:

1. A fusion peptide comprising three or more repeats of an immunogenic peptide, wherein the immunogenic peptide is selected from (a) a peptide comprising the sequence GYMLGSAMSRP (SEQ ID NO:17); (b) a peptide comprising the sequence VDQYSNQNNF (SEQ ID NO:19); or (c) a peptide comprising a sequence corresponding to GYMLGSAMSRP (SEQ ID NO:17) or VDQYSNQNNF (SEQ ID NO:19) from another non-bovine mammalian species,
wherein one or more of the repeats is in an inverted orientation.

2. The fusion peptide of claim 1 , wherein said fusion peptide comprises the amino acid sequence of SEQ ID NO:38.

3. The fusion peptide of claim 1 , wherein said fusion peptide comprises the amino acid sequence of SEQ ID NO:43.

4. The fusion peptide of claim 1 , wherein said fusion peptide comprises the amino acid sequence of SEQ ID NO:48.

5. The fusion peptide of claim 1 , linked to a carrier molecule.

6. The fusion peptide of claim 5 , wherein the carrier molecule is an RTX toxin characterized by a carboxy-terminus consensus amino acid sequence of Gly-Gly-X-Gly-X-Asp (SEQ ID NO: 11) wherein X is Lys, Asp, Val or Asn.

7. The fusion peptide of claim 6 , wherein the carrier molecule is a leukotoxin polypeptide.

8. The fusion peptide of claim 7 , wherein the leukotoxin polypeptide is leukotoxin (LKT) 352.

9. The fusion peptide of claim 5 , wherein the carrier molecule is a lyssavirus glcoprotein G or a portion thereof comprising a deletion of all or part of the C-terminal transmembrane and cytoplasmic domains.

10. The fusion peptide of claim 9 , wherein the lyssavirus glycoprotein G comprises the sequence of amino acids of SEQ ID NO:49.

11. A composition comprising the fusion peptide of claim 1 , and a pharmaceutically acceptable vehicle.

12. The composition of claim 11 comprising a fusion peptide with the amino acid sequence of SEQ ID NO:38, and a fusion peptide with the amino acid sequence of SEQ ID NO:43 or SEQ ID NO:48.

13. The composition of claim 12 , further comprising a fusion peptide with the amino acid sequence of SEQ ID NO:37.

14. A method of producing a composition comprising combining the fusion peptide of claim 1 with a pharmaceutically acceptable vehicle.

15. An immunodiagnostic test kit for detecting prion infection, said test kit comprising the fusion peptide according to claim 1 , and instructions for conducting the immunodiagnostic test.

16. A method of eliciting an immune response to a prion in a mammal comprising administering to said mammal an immunologically effective amount of the composition of claim 11 .

17. A method of detecting presence or absence of prion antibodies in a biological sample comprising:
(a) providing a biological sample;
(b) reacting said biological sample with the fusion peptide of claim 1 under conditions which allow prion antibodies, when present in the biological sample, to bind specifically to said fusion peptide to form an antibody-antigen complex; and
(c) detecting the presence or the absence of said complex, thereby detecting the presence or the absence of the prion antibodies in said sample.

Assignees

• Univ Saskatchewan

Inventors

• Marciniuk Kristen
• Taschuk Ryan
• Napper Scott
• Potter Andrew
• Cashman Neil

Classifications

• G01N33/6854

  Immunoglobulins · CPC title

• C07K14/47

  from mammals · CPC title

• A61K39/0007

  Nervous system antigens; Prions · CPC title

• A61P37/04

  Immunostimulants · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title